Join this webinar session for case study examples that demonstrate how innovative pharma marketers are utilizing social networks as a force for good to cultivate lasting consumer relationships and improve patient outcomes. Learn what’s working – and what pitfalls to avoid – in today’s rapidly evolving digital landscape.
A panel of experts and leaders across healthcare, biopharma, and high tech will explore how to break down silos and think like a learning health ecosystem.
Life science companies gather and generate large amounts of data; however, this data often remains widely untouched, ungoverned, unstructured, and stored in disparate silos. In 2022 and beyond, life sciences organizations that uncover how to make use of their expansive data will be positioned to distinguish themselves competitively.
Inflammation: A necessity and a threat to COVID-19 patientsAnti-Inflammatory, Antibodies, Biology, Coronavirus Disease (COVID-19) Pandemic, COVID-19 Vaccines, Cytokines, Fall/Autumn, Inflammation, Patient Outcomes, SARS-CoV-2 virus, Symptoms: Coronavirus Disease 2019 (COVID-19), Tumor Necrosis Factor (TNF), Winter
Blocking TNF production could offer a more effective solution for the treatment of COVID-19.
EVERSANA, a pioneer of next-generation commercial services to the global life sciences industry, partnered with WorldQuant Predictive (WQP), a market leader in quantitative predictions and data-driven decisions through a cloud-based artificial intelligence (AI) platform, to improve the end result for patients.
MJH Life Sciences™ Launches COVID-19 Coalition — Alliance of renowned thought leaders to assemble biweekly to keep health care professionals abreast of emerging COVID-19 science and news. […]
The age of blockbuster drugs has officially given way to precision medicines that are customized for rare diseases and individual patients. We are in the early days of a decades-long trend that will influence changes throughout the entire life sciences industry and lead to groundbreaking cures and treatments.
The U.S. Centers for Medicare and Medicaid Services finalized a decision to cover expensive cancer cell therapies sold by Gilead Sciences Inc. and Novartis AG.
Johnson & Johnson plunked down $3.4 billion in cash to acquire privately held Auris Health Inc., a company that has developed robotic endoscopic technologies for the treatment of lung cancer.
Predictive analytics have transformed the way the telecom industry communicates with existing customers and distributes its resources to maximize customer retention. Can healthcare companies leverage the same analytics techniques to combat patient non-adherence?